Form 8-K - Current report:
SEC Accession No. 0001193125-24-251240
Filing Date
2024-11-05
Accepted
2024-11-05 16:05:32
Documents
13
Period of Report
2024-11-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d872811d8k.htm   iXBRL 8-K 23324
  Complete submission text file 0001193125-24-251240.txt   149159

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA antx-20241104.xsd EX-101.SCH 2874
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20241104_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20241104_pre.xml EX-101.PRE 11723
15 EXTRACTED XBRL INSTANCE DOCUMENT d872811d8k_htm.xml XML 3759
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 241427428
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)